Influence of serum and soluble CD25 (sCD25) on regulatory and effector T-cell function in hepatocellular carcinoma

Scandinavian Journal of Immunology

Volumn 72, Issue 4, 2010, Pages 293-301

  Cabrera, R ^a   Ararat, M ^a   Eksioglu, E A ^a   Cao, M ^a   Xu, Y ^a   Wasserfall, C ^a   Atkinson, M A ^a   Liu, C ^a   Nelson, D R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CULTURE MEDIUM; IL2RA PROTEIN, HUMAN; INTERLEUKIN 2 RECEPTOR ALPHA;

BLOOD; CELL CULTURE; CELL PROLIFERATION; CULTURE MEDIUM; CYTOLOGY; DRUG EFFECTS; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; PHARMACOLOGY; REGULATORY T LYMPHOCYTE; SOLUBILITY; T LYMPHOCYTE;

CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LIVER NEOPLASMS; SOLUBILITY; T-LYMPHOCYTES; T-LYMPHOCYTES, REGULATORY;

EID: 77956328387     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2010.02427.x     Document Type: Article

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001 94 : 153 156.
2. Smith KA, Popmihajlov Z. The quantal theory of immunity and the interleukin-2-dependent negative feedback regulation of the immune response. Immunol Rev 2008 224 : 124 140.
3. Cao M, Cabrera R, Xu Y et al. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells. Lab Invest 2007 87 : 582 590.
4. Waldmann H, Cobbold S. Regulatory T cells: context matters. Immunity 2009 30 : 613 615.
5. Foss FM. Immunologic mechanisms of antitumor activity. Semin Oncol 2002 29 : 5 11.
6. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004 22 : 329 360.
7. Unitt E, Marshall A, Gelson W et al. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol 2006 45 : 246 253.
8. Ozaki K, Leonard WJ. Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem 2002 277 : 29355 29358.
9. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol 2009 21 : 1105 1111.
10. Baecher-Allan C, Viglietta V, Hafler DA. Human CD4+CD25+ regulatory T cells. Semin Immunol 2004 16 : 89 98.
11. Corthay A. How do regulatory T cells work? Scand J Immunol 2009 70 : 326 336.
12. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009 30 : 636 645.
13. Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol 2008 8 : 523 532.
14. Rudensky AY, Campbell DJ. In vivo sites and cellular mechanisms of T reg cellmediated suppression. J Exp Med 2006 203 : 489 492.
15. Vercoulen Y, Wehrens EJ, van Teijlingen NH, de Jager W, Beekman JM, Prakken BJ. Human regulatory T cell suppressive function is independent of apoptosis induction in activated effector T cells. PLoS ONE 2009 4 : e7183.
16. Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv Immunol 1998 70 : 1 81.
17. Cabrera R, Ararat M, Cao M et al. Hepatocellular carcinoma immunopathogenesis: clinical evidence for global T cell defects and an immunomodulatory role for soluble CD25 (sCD25). Dig Dis Sci 2010 55 : 484 495.
18. Cabrera R, Tu Z, Xu Y et al. An immunomodulatory role for CD4(+)CD25(+) regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004 40 : 1062 1071.
19. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998 188 : 287 296.
20. Takahashi T, Kuniyasu Y, Toda M et al. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998 10 : 1969 1980.
21. Ormandy LA, Hillemann T, Wedemeyer H, Manns MP, Greten TF, Korangy F. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res 2005 65 : 2457 2464.
22. Yang XH, Yamagiwa S, Ichida T et al. Increase of CD4+CD25+ regulatory Tcells in the liver of patients with hepatocellular carcinoma. J Hepatol 2006 45 : 254 262.
23. Szymczak-Workman AL, Workman CJ, Vignali DA. Cutting edge: regulatory T cells do not require stimulation through their TCR to suppress. J Immunol 2009 182 : 5188 5192.
24. Oberg HH, Wesch D, Lenke J, Kabelitz D. An optimized method for the functional analysis of human regulatory T cells. Scand J Immunol 2006 64 : 353 360.
25. Brusko TM, Wasserfall CH, Hulme MA, Cabrera R, Schatz D, Atkinson MA. Influence of membrane CD25 stability on T lymphocyte activity: implications fo immunoregulation. PLoS ONE 2009 4 : e7980.
26. Pedersen AE, Lauritsen JP. CD25 shedding by human natural occurring CD4+CD25+ regulatory T cells does not inhibit the action of IL-2. Scand J Immunol 2009 70 : 40 3.
27. Maier LM, Anderson DE, Severson CA et al. Soluble IL-2RA levels in multiple sclerosis subjects and the effect of soluble IL-2RA on immune responses. J Immunol 2009 182 : 1541 1547.
28. Sereti I, Gea-Banacloche J, Kan MY, Hallahan CW, Lane HC. Interleukin 2 leads to dose-dependent expression of the alpha chain of the IL-2 receptor on CD25-negative T lymphocytes in the absence of exogenous antigenic stimulation. Clin Immunol 2000 97 : 266 276.